Relevance of the lectin pathway of complement in rheumatic diseases

Advances in Clinical Chemistry

Volumn 56, Issue , 2012, Pages 105-153

  Boldt, Angelica B W ^a   Goeldner, Isabela ^a   De Messias Reason, Iara J T ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Complement; Ficolin; Immune response; Mannose binding lectin; MASP

Indexed keywords

EID: 84855337409     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394317-0.00012-1     Document Type: Chapter

References (297)

1. Hoffmann J.A., Kafatos F.C., Janeway C.A., Ezekowitz R.A. Phylogenetic perspectives in innate immunity. Science 1999, 284:1313-1318.
2. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
3. Malhotra R., Wormald M.R., Rudd P.M., Fischer P.B., Dwek R.A., Sim R.B. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat. Med. 1995, 1:237-243.
4. Tregoat V., Montagne P., Bene M.C., Faure G. Changes in the mannan binding lectin (MBL) concentration in human milk during lactation. J. Clin. Lab. Anal. 2002, 16:304-307.
5. Seyfarth J., Garred P., Madsen H.O. Extra-hepatic transcription of the human mannose-binding lectin gene (mbl2) and the MBL-associated serine protease 1-3 genes. Mol. Immunol. 2006, 43:962-971.
6. Sjoberg A.P., Manderson G.A., Morgelin M., Day A.J., Heinegard D., Blom A.M. Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol. Immunol. 2009, 46:830-839.
7. Swingler T.E., Waters J.G., Davidson R.K., et al. Degradome expression profiling in human articular cartilage. Arthritis Res. Ther. 2009, 11:R96.
8. Dunkelberger J.R., Song W.C. Complement and its role in innate and adaptive immune responses. Cell Res. 2010, 20:34-50.
9. Degn S.E., Thiel S., Jensenius J.C. New perspectives on mannan-binding lectin-mediated complement activation. Immunobiology 2007, 212:301-311.
10. Matsushita M., Thiel S., Jensenius J.C., Terai I., Fujita T. Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J. Immunol. 2000, 165:2637-2642.
11. Happonen K.E., Saxne T., Aspberg A., Morgelin M., Heinegard D., Blom A.M. Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis. Arthritis Rheum. 2010, 62:3574-3583.
12. Sjoberg A.P., Trouw L.A., Blom A.M. Complement activation and inhibition: a delicate balance. Trends Immunol. 2009, 30:83-90.
13. Geyer M., Grassel S., Straub R.H., et al. Differential transcriptome analysis of intraarticular lesional vs intact cartilage reveals new candidate genes in osteoarthritis pathophysiology. Osteoarthritis Cartilage 2009, 17:328-335.
14. Degn S.E., Hansen A.G., Steffensen R., Jacobsen C., Jensenius J.C., Thiel S. MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation. J. Immunol. 2009, 183:7371-7378.
15. Thiel S. Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol. Immunol. 2007, 44:3875-3888.
16. Jensenius J.C. The mannan-binding lectin (MBL) pathway of complement activation: biochemistry, biology and clinical implications. Adv. Exp. Med. Biol. 2005, 564:21-22.
17. Holmskov U., Thiel S., Jensenius J.C. Collections and ficolins: humoral lectins of the innate immune defense. Annu. Rev. Immunol. 2003, 21:547-578.
18. Bohlson S.S., Fraser D.A., Tenner A.J. Complement proteins C1q and MBL are pattern recognition molecules that signal immediate and long-term protective immune functions. Mol. Immunol. 2007, 44:33-43.
19. Endo Y., Takahashi M., Fujita T. Lectin complement system and pattern recognition. Immunobiology 2006, 211:283-293.
20. Mogues T., Ota T., Tauber A.I., Sastry K.N. Characterization of two mannose-binding protein cDNAs from rhesus monkey (Macaca mulatta): structure and evolutionary implications. Glycobiology 1996, 6:543-550.
21. Seyfarth J., Garred P., Madsen H.O. The 'involution' of mannose-binding lectin. Hum. Mol. Genet. 2005, 14:2859-2869.
22. Kurata H., Sannoh T., Kozutsumi Y., Yokota Y., Kawasaki T. Structure and function of mannan-binding proteins isolated from human liver and serum. J. Biochem. 1994, 115:1148-1154.
23. Sastry K., Herman G.A., Day L., et al. The human mannose-binding protein gene. Exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10. J. Exp. Med. 1989, 170:1175-1189.
24. Guo N., Mogues T., Weremowicz S., Morton C.C., Sastry K.N. The human ortholog of rhesus mannose-binding protein-A gene is an expressed pseudogene that localizes to chromosome 10. Mamm. Genome 1998, 9:246-249.
25. Ezekowitz R.A., Stahl P.D. The structure and function of vertebrate mannose lectin-like proteins. J. Cell Sci. Suppl. 1988, 9:121-133.
26. Schweinle J.E., Nishiyasu M., Ding T.Q., Sastry K., Gillies S.D., Ezekowitz R.A. Truncated forms of mannose-binding protein multimerize and bind to mannose-rich Salmonella montevideo but fail to activate complement in vitro. J. Biol. Chem. 1993, 268:364-370.
27. Ezekowitz R.A., Day L.E., Herman G.A. A human mannose-binding protein is an acute-phase reactant that shares sequence homology with other vertebrate lectins. J. Exp. Med. 1988, 167:1034-1046.
28. Weis W.I., Taylor M.E., Drickamer K. The C-type lectin superfamily in the immune system. Immunol. Rev. 1998, 163:19-34.
29. Larsen F., Madsen H.O., Sim R.B., Koch C., Garred P. Disease-associated mutations in human mannose-binding lectin compromise oligomerization and activity of the final protein. J. Biol. Chem. 2004, 279:21302-21311.
30. Wallis R., Drickamer K. Molecular determinants of oligomer formation and complement fixation in mannose-binding proteins. J. Biol. Chem. 1999, 274:3580-3589.
31. Yokota Y., Arai T., Kawasaki T. Oligomeric structures required for complement activation of serum mannan-binding proteins. J. Biochem. 1995, 117:414-419.
32. Lu J.H., Thiel S., Wiedemann H., Timpl R., Reid K.B. Binding of the pentamer/hexamer forms of mannan-binding protein to zymosan activates the proenzyme C1r2C1s2 complex, of the classical pathway of complement, without involvement of C1q. J. Immunol. 1990, 144:2287-2294.
33. Kawasaki N., Kawasaki T., Yamashina I. Isolation and characterization of a mannan-binding protein from human serum. J. Biochem. 1983, 94:937-947.
34. Lee R.T., Ichikawa Y., Fay M., Drickamer K., Shao M.C., Lee Y.C. Ligand-binding characteristics of rat serum-type mannose-binding protein (MBP-A). Homology of binding site architecture with mammalian and chicken hepatic lectins. J. Biol. Chem. 1991, 266:4810-4815.
35. Arai T., Tabona P., Summerfield J.A. Human mannose-binding protein gene is regulated by interleukins, dexamethasone and heat shock. Q. J. Med. 1993, 86:575-582.
36. Thiel S., Holmskov U., Hviid L., Laursen S.B., Jensenius J.C. The concentration of the C-type lectin, mannan-binding protein, in human plasma increases during an acute phase response. Clin. Exp. Immunol. 1992, 90:31-35.
37. Steffensen R., Thiel S., Varming K., Jersild C., Jensenius J.C. Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J. Immunol. Methods 2000, 241:33-42.
38. van de Geijn F.E., Dolhain R.J., van Rijs W., Hazes J.M., de Groot C.J. Mannose-binding lectin genotypes and pre-eclampsia: a case-control study. Hum. Immunol. 2007, 68:888-893.
39. Csuka D., Molvarec A., Derzsy Z., et al. Functional analysis of the mannose-binding lectin complement pathway in normal pregnancy and preeclampsia. J. Reprod. Immunol. 2010, 87:90-96.
40. Aittoniemi J., Miettinen A., Laippala P., et al. Age-dependent variation in the serum concentration of mannan-binding protein. Acta Paediatr. 1996, 85:906-909.
41. Terai I., Kobayashi K. Perinatal changes in serum mannose-binding protein (MBP) levels. Immunol. Lett. 1993, 38:185-187.
42. Thiel S., Bjerke T., Hansen D., Poulsen L.K., Schiotz P.O., Jensenius J.C. Ontogeny of human mannan-binding protein, a lectin of the innate immune system. Pediatr. Allergy Immunol. 1995, 6:20-23.
43. Super M., Thiel S., Lu J., Levinsky R.J., Turner M.W. Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet 1989, 2:1236-1239.
44. Dommett R.M., Klein N., Turner M.W. Mannose-binding lectin in innate immunity: past, present and future. Tissue Antigens 2006, 68:193-209.
45. Ambrosio A.R., Messias-Reason I.J. Leishmania (Viannia) braziliensis: interaction of mannose-binding lectin with surface glycoconjugates and complement activation. An antibody-independent defence mechanism. Parasite Immunol. 2005, 27:333-340.
46. Jack D.L., Turner M.W. Anti-microbial activities of mannose-binding lectin. Biochem. Soc. Trans. 2003, 31:753-757.
47. Klabunde J., Berger J., Jensenius J.C., et al. Schistosoma mansoni: adhesion of mannan-binding lectin to surface glycoproteins of cercariae and adult worms. Exp. Parasitol. 2000, 95:231-239.
48. Klabunde J., Uhlemann A.C., Tebo A.E., et al. Recognition of plasmodium falciparum proteins by mannan-binding lectin, a component of the human innate immune system. Parasitol. Res. 2002, 88:113-117.
49. Nauta A.J., Castellano G., Xu W., et al. Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells. J. Immunol. 2004, 173:3044-3050.
50. Weis W.I., Drickamer K., Hendrickson W.A. Structure of a C-type mannose-binding protein complexed with an oligosaccharide. Nature 1992, 360:127-134.
51. Kilpatrick D.C. Phospholipid-binding activity of human mannan-binding lectin. Immunol. Lett. 1998, 61:191-195.
52. Palaniyar N., Nadesalingam J., Reid K.B. Innate immune collectins bind nucleic acids and enhance DNA clearance in vitro. Ann. N. Y. Acad. Sci. 2003, 1010:467-470.
53. Estabrook M.M., Jack D.L., Klein N.J., Jarvis G.A. Mannose-binding lectin binds to two major outer membrane proteins, opacity protein and porin, of Neisseria meningitidis. J. Immunol. 2004, 172:3784-3792.
54. Jack D.L., Dodds A.W., Anwar N., et al. Activation of complement by mannose-binding lectin on isogenic mutants of Neisseria meningitidis serogroup B. J. Immunol. 1998, 160:1346-1353.
55. Tenner A.J., Robinson S.L., Ezekowitz R.A. Mannose binding protein (MBP) enhances mononuclear phagocyte function via a receptor that contains the 126,000 M(r) component of the C1q receptor. Immunity 1995, 3:485-493.
56. Kang H.J., Lee S.M., Lee H.H., et al. Mannose-binding lectin without the aid of its associated serine proteases alters lipopolysaccharide-mediated cytokine/chemokine secretion from human endothelial cells. Immunology 2007, 122:335-342.
57. Ogden C.A., deCathelineau A., Hoffmann P.R., et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J. Exp. Med. 2001, 194:781-795.
58. Stuart L.M., Takahashi K., Shi L., Savill J., Ezekowitz R.A. Mannose-binding lectin-deficient mice display defective apoptotic cell clearance but no autoimmune phenotype. J. Immunol. 2005, 174:3220-3226.
59. Walsh M.C., Bourcier T., Takahashi K., et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J. Immunol. 2005, 175:541-546.
60. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 2001, 491:369-402.
61. Nakagawa T., Kawasaki N., Ma Y., Uemura K., Kawasaki T. Antitumor activity of mannan-binding protein. Methods Enzymol. 2003, 363:26-33.
62. Radcliffe C.M., Arnold J.N., Suter D.M., et al. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J. Biol. Chem. 2007, 282:7405-7415.
63. Bernig T., Taylor J.G., Foster C.B., Staats B., Yeager M., Chanock S.J. Sequence analysis of the mannose-binding lectin (MBL2) gene reveals a high degree of heterozygosity with evidence of selection. Genes Immun. 2004, 5:461-476.
64. Boldt A.B., Messias-Reason I.J., Meyer D., et al. Phylogenetic nomenclature and evolution of mannose-binding lectin (MBL2) haplotypes. BMC Genet. 2010, 11:38.
65. Boldt A.B., Culpi L., Tsuneto L.T., de Souza I.R., Kun J.F., Petzl-Erler M.L. Diversity of the MBL2 gene in various Brazilian populations and the case of selection at the mannose-binding lectin locus. Hum. Immunol. 2006, 67:722-734.
66. Boldt A.B., Luty A., Grobusch M.P., et al. Association of a new mannose-binding lectin variant with severe malaria in Gabonese children. Genes Immun. 2006, 7:393-400.
67. Verdu P., Barreiro L.B., Patin E., et al. Evolutionary insights into the high worldwide prevalence of MBL2 deficiency alleles. Hum. Mol. Genet. 2006, 15:2650-2658.
68. Gabolde M., Muralitharan S., Besmond C. Genotyping of the three major allelic variants of the human mannose-binding lectin gene by denaturing gradient gel electrophoresis. Hum. Mutat. 1999, 14:80-83.
69. Madsen H.O., Garred P., Thiel S., et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J. Immunol. 1995, 155:3013-3020.
70. Madsen H.O., Satz M.L., Hogh B., Svejgaard A., Garred P. Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J. Immunol. 1998, 161:3169-3175.
71. Butler G.S., Sim D., Tam E., Devine D., Overall C.M. Mannose-binding lectin (MBL) mutants are susceptible to matrix metalloproteinase proteolysis: potential role in human MBL deficiency. J. Biol. Chem. 2002, 277:17511-17519.
72. Ip W.K., To Y.F., Cheng S.K., Lau Y.L. Serum mannose-binding lectin levels and mbl2 gene polymorphisms in different age and gender groups of southern Chinese adults. Scand. J. Immunol. 2004, 59:310-314.
73. Minchinton R.M., Dean M.M., Clark T.R., Heatley S., Mullighan C.G. Analysis of the relationship between mannose-binding lectin (MBL) genotype, MBL levels and function in an Australian blood donor population. Scand. J. Immunol. 2002, 56:630-641.
74. Turner M.W., Dinan L., Heatley S., et al. Restricted polymorphism of the mannose-binding lectin gene of indigenous Australians. Hum. Mol. Genet. 2000, 9:1481-1486.
75. Lee S.G., Yum J.S., Moon H.M., et al. Analysis of mannose-binding lectin 2 (MBL2) genotype and the serum protein levels in the Korean population. Mol. Immunol. 2005, 42:969-977.
76. Schafranski M.D., Stier A., Nisihara R., Messias-Reason I.J. Significantly increased levels of mannose-binding lectin (MBL) in rheumatic heart disease: a beneficial role for MBL deficiency. Clin. Exp. Immunol. 2004, 138:521-525.
77. Boldt A.B., Petzl-Erler M.L. A new strategy for mannose-binding lectin gene haplotyping. Hum. Mutat. 2002, 19:296-306.
78. Dean M.M., Heatley S., Minchinton R.M. Heteroligomeric forms of codon 54 mannose binding lectin (MBL) in circulation demonstrate reduced in vitro function. Mol. Immunol. 2006, 43:950-961.
79. Wiertsema S.P., Herpers B.L., Veenhoven R.H., et al. Functional polymorphisms in the mannan-binding lectin 2 gene: effect on MBL levels and otitis media. J. Allergy Clin. Immunol. 2006, 117:1344-1350.
80. Tsutsumi A., Takahashi R., Sumida T. Mannose binding lectin: genetics and autoimmune disease. Autoimmun. Rev. 2005, 4:364-372.
81. Miller M.E., Seals J., Haye R., Levitsky L.C. A familial plasma-associated defect of phagocytosis. Lancet 1968, 2:60-63.
82. Sumiya M., Super M., Tabona P., et al. Molecular basis of opsonic defect in immunodeficient children. Lancet 1991, 337:1569-1570.
83. Arnold J.N., Dwek R.A., Rudd P.M., Sim R.B. Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunol. Lett. 2006, 106:103-110.
84. Eisen D.P., Minchinton R.M. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin. Infect. Dis. 2003, 37:1496-1505.
85. Aittoniemi J., Baer M., Soppi E., Vesikari T., Miettinen A. Mannan binding lectin deficiency and concomitant immunodefects. Arch. Dis. Child. 1998, 78:245-248.
86. Dahl M., Tybjaerg-Hansen A., Schnohr P., Nordestgaard B.G. A population-based study of morbidity and mortality in mannose-binding lectin deficiency. J. Exp. Med. 2004, 199:1391-1399.
87. Messias Reason I.J., Schafranski M.D., Jensenius J.C., Steffensen R. The association between mannose-binding lectin gene polymorphism and rheumatic heart disease. Hum. Immunol. 2006, 67:991-998.
88. Bilgin Y.M., Brand A., Berger S.P., Daha M.R., Roos A. Mannose-binding lectin is involved in multiple organ dysfunction syndrome after cardiac surgery: effects of blood transfusions. Transfusion 2008, 48:601-608.
89. Dornelles L.N., Pereira-Ferrari L., Messias-Reason I. Mannan-binding lectin plasma levels in leprosy: deficiency confers protection against the lepromatous but not the tuberculoid forms. Clin. Exp. Immunol. 2006, 145:463-468.
90. Messias-Reason I.J., Boldt A.B., Moraes Braga A.C., et al. The association between mannan-binding lectin gene polymorphism and clinical leprosy: new insight into an old paradigm. J. Infect. Dis. 2007, 196:1379-1385.
91. Santos I.K., Costa C.H., Krieger H., et al. Mannan-binding lectin enhances susceptibility to visceral leishmaniasis. Infect. Immun. 2001, 69:5212-5215.
92. Soborg C., Madsen H.O., Andersen A.B., Lillebaek T., Kok-Jensen A., Garred P. Mannose-binding lectin polymorphisms in clinical tuberculosis. J. Infect. Dis. 2003, 188:777-782.
93. Thye T., Vannberg F.O., Wong S.H., et al. Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2. Nat. Genet. 2010, 42:739-741.
94. Soothill J.F., Harvey B.A. Defective opsonization. A common immunity deficiency. Arch. Dis. Child. 1976, 51:91-99.
95. Valdimarsson H., Stefansson M., Vikingsdottir T., et al. Reconstitution of opsonizing activity by infusion of mannan-binding lectin (MBL) to MBL-deficient humans. Scand. J. Immunol. 1998, 48:116-123.
96. Ichijo H., Ronnstrand L., Miyagawa K., Ohashi H., Heldin C.H., Miyazono K. Purification of transforming growth factor-beta 1 binding proteins from porcine uterus membranes. J. Biol. Chem. 1991, 266:22459-22464.
97. Omori-Satoh T., Yamakawa Y., Mebs D. The antihemorrhagic factor, erinacin, from the European hedgehog (Erinaceus europaeus), a metalloprotease inhibitor of large molecular size possessing ficolin/opsonin P35 lectin domains. Toxicon 2000, 38:1561-1580.
98. Kenjo A., Takahashi M., Matsushita M., et al. Cloning and characterization of novel ficolins from the solitary ascidian, Halocynthia roretzi. J. Biol. Chem. 2001, 276:19959-19965.
99. Endo Y., Liu Y., Fujita T. Structure and function of ficolins. Adv. Exp. Med. Biol. 2006, 586:265-279.
100. Endo Y., Matsushita M., Fujita T. Role of ficolin in innate immunity and its molecular basis. Immunobiology 2007, 212:371-379.
101. Matsushita M., Endo Y., Taira S., et al. A novel human serum lectin with collagen- and fibrinogen-like domains that functions as an opsonin. J. Biol. Chem. 1996, 271:2448-2454.
102. Krarup A., Thiel S., Hansen A., Fujita T., Jensenius J.C. L-ficolin is a pattern recognition molecule specific for acetyl groups. J. Biol. Chem. 2004, 279:47513-47519.
103. Teh C., Le Y., Lee S.H., Lu J. M-ficolin is expressed on monocytes and is a lectin binding to N-acetyl-D-glucosamine and mediates monocyte adhesion and phagocytosis of Escherichia coli. Immunology 2000, 101:225-232.
104. Sugimoto R., Yae Y., Akaiwa M., et al. Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family. J. Biol. Chem. 1998, 273:20721-20727.
105. Endo Y., Sato Y., Matsushita M., Fujita T. Cloning and characterization of the human lectin P35 gene and its related gene. Genomics 1996, 36:515-521.
106. Rorvig S., Honore C., Larsson L.I., et al. Ficolin-1 is present in a highly mobilizable subset of human neutrophil granules and associates with the cell surface after stimulation with fMLP. J. Leukoc. Biol. 2009, 86:1439-1449.
107. Wittenborn T., Thiel S., Jensen L.T., Nielsen H.J., Jensen L., Jensenius J.C. Characteristics and biological variations of M-ficolin, a pattern recognition molecule, in plasma. J. Innate Immun. 2009, 2:167-180.
108. Liu Y., Endo Y., Iwaki D., et al. Human M-ficolin is a secretory protein that activates the lectin complement pathway. J. Immunol. 2005, 175:3150-3156.
109. Garlatti V., Martin L., Gout E., et al. Structural basis for innate immune sensing by M-ficolin and its control by a pH-dependent conformational switch. J. Biol. Chem. 2007, 282:35814-35820.
110. Gout E., Garlatti V., Smith D.F., et al. Carbohydrate recognition properties of human ficolins: glycan array screening reveals the sialic acid binding specificity of M-ficolin. J. Biol. Chem. 2010, 285:6612-6622.
111. Runza V.L., Hehlgans T., Echtenacher B., Zahringer U., Schwaeble W.J., Mannel D.N. Localization of the mouse defense lectin ficolin B in lysosomes of activated macrophages. J. Endotoxin Res. 2006, 12:120-126.
112. Tanio M., Wakamatsu K., Kohno T. Binding site of C-reactive protein on M-ficolin. Mol. Immunol. 2009, 47:215-221.
113. Tanio M., Kondo S., Sugio S., Kohno T. Trivalent recognition unit of innate immunity system: crystal structure of trimeric human M-ficolin fibrinogen-like domain. J. Biol. Chem. 2007, 282:3889-3895.
114. Honore C., Rorvig S., Munthe-Fog L., et al. The innate pattern recognition molecule Ficolin-1 is secreted by monocytes/macrophages and is circulating in human plasma. Mol. Immunol. 2008, 45:2782-2789.
115. Lu J., Tay P.N., Kon O.L., Reid K.B. Human ficolin: cDNA cloning, demonstration of peripheral blood leucocytes as the major site of synthesis and assignment of the gene to chromosome 9. Biochem. J. 1996, 313(Pt 2):473-478.
116. Hummelshoj T., Munthe-Fog L., Madsen H.O., Garred P. Functional SNPs in the human ficolin (FCN) genes reveal distinct geographical patterns. Mol. Immunol. 2008, 45:2508-2520.
117. Schlapbach L.J., Kessler U., Thiel S., et al. M-ficolin in the neonatal period: associations with need for mechanical ventilation and mortality in premature infants with necrotising enterocolitis. Mol. Immunol. 2009, 46:2597-2603.
118. Hummelshoj T., Fog L.M., Madsen H.O., Sim R.B., Garred P. Comparative study of the human ficolins reveals unique features of Ficolin-3 (Hakata antigen). Mol. Immunol. 2008, 45:1623-1632.
119. Munthe-Fog L., Hummelshoj T., Hansen B.E., et al. The impact of FCN2 polymorphisms and haplotypes on the Ficolin-2 serum levels. Scand. J. Immunol. 2007, 65:383-392.
120. Le Y., Tan S.M., Lee S.H., Kon O.L., Lu J. Purification and binding properties of a human ficolin-like protein. J. Immunol. Methods 1997, 204:43-49.
121. Le Y., Lee S.H., Kon O.L., Lu J. Human L-ficolin: plasma levels, sugar specificity, and assignment of its lectin activity to the fibrinogen-like (FBG) domain. FEBS Lett. 1998, 425:367-370.
122. Faro J., Chen Y., Jhaveri P., et al. L-ficolin binding and lectin pathway activation by acetylated low-density lipoprotein. Clin. Exp. Immunol. 2008, 151:275-283.
123. Garlatti V., Belloy N., Martin L., et al. Structural insights into the innate immune recognition specificities of L- and H-ficolins. EMBO J. 2007, 26:623-633.
124. Harumiya S., Omori A., Sugiura T., Fukumoto Y., Tachikawa H., Fujimoto D. EBP-37, a new elastin-binding protein in human plasma: structural similarity to ficolins, transforming growth factor-beta 1-binding proteins. J. Biochem. 1995, 117:1029-1035.
125. Krarup A., Sorensen U.B., Matsushita M., Jensenius J.C., Thiel S. Effect of capsulation of opportunistic pathogenic bacteria on binding of the pattern recognition molecules mannan-binding lectin, L-ficolin, and H-ficolin. Infect. Immun. 2005, 73:1052-1060.
126. Aoyagi Y., Adderson E.E., Rubens C.E., et al. L-Ficolin/mannose-binding lectin-associated serine protease complexes bind to group B streptococci primarily through N-acetylneuraminic acid of capsular polysaccharide and activate the complement pathway. Infect. Immun. 2008, 76:179-188.
127. Ma Y.G., Cho M.Y., Zhao M., et al. Human mannose-binding lectin and L-ficolin function as specific pattern recognition proteins in the lectin activation pathway of complement. J. Biol. Chem. 2004, 279:25307-25312.
128. Carroll M.V., Lack N., Sim E., Krarup A., Sim R.B. Multiple routes of complement activation by Mycobacterium bovis BCG. Mol. Immunol. 2009, 46:3367-3378.
129. Liu J., Ali M.A., Shi Y., et al. Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell. Mol. Immunol. 2009, 6:235-244.
130. Evans-Osses I., Ansa-Addo E.A., Inal J.M., Ramirez M.I. Involvement of lectin pathway activation in the complement killing of Giardia intestinalis. Biochem. Biophys. Res. Commun. 2010, 395:382-386.
131. Cestari I.S., Krarup A., Sim R.B., Inal J.M., Ramirez M.I. Role of early lectin pathway activation in the complement-mediated killing of Trypanosoma cruzi. Mol. Immunol. 2009, 47:426-437.
132. Michelow I.C., Dong M., Mungall B.A., et al. A novel L-ficolin/mannose-binding lectin chimeric molecule with enhanced activity against Ebola virus. J. Biol. Chem. 2010, 285:24729-24739.
133. Chang W.C., Hartshorn K.L., White M.R., et al. Recombinant chimeric lectins consisting of mannose-binding lectin and L-ficolin are potent inhibitors of influenza A virus compared with mannose-binding lectin. Biochem. Pharmacol. 2010, 81:388-395.
134. Zhang J., Koh J., Lu J., et al. Local inflammation induces complement crosstalk which amplifies the antimicrobial response. PLoS Pathog. 2009, 5:e1000282.
135. Kuraya M., Ming Z., Liu X., Matsushita M., Fujita T. Specific binding of L-ficolin and H-ficolin to apoptotic cells leads to complement activation. Immunobiology 2005, 209:689-697.
136. Jensen M.L., Honore C., Hummelshoj T., Hansen B.E., Madsen H.O., Garred P. Ficolin-2 recognizes DNA and participates in the clearance of dying host cells. Mol. Immunol. 2007, 44:856-865.
137. Hummelshoj T., Munthe-Fog L., Madsen H.O., Fujita T., Matsushita M., Garred P. Polymorphisms in the FCN2 gene determine serum variation and function of Ficolin-2. Hum. Mol. Genet. 2005, 14:1651-1658.
138. Cedzynski M., Nuytinck L., Atkinson A.P., et al. Extremes of L-ficolin concentration in children with recurrent infections are associated with single nucleotide polymorphisms in the FCN2 gene. Clin. Exp. Immunol. 2007, 150:99-104.
139. Herpers B.L., Immink M.M., de Jong B.A., Velzen-Blad H., de Jongh B.M., van Hannen E.J. Coding and non-coding polymorphisms in the lectin pathway activator L-ficolin gene in 188 Dutch blood bank donors. Mol. Immunol. 2006, 43:851-855.
140. Kilpatrick D.C., Chalmers J.D., MacDonald S.L., et al. Stable bronchiectasis is associated with low serum L-ficolin concentrations. Clin. Respir. J. 2009, 3:29-33.
141. Atkinson A.P., Cedzynski M., Szemraj J., et al. L-ficolin in children with recurrent respiratory infections. Clin. Exp. Immunol. 2004, 138:517-520.
142. Cedzynski M., Atkinson A.P., St S.A., et al. L-ficolin (ficolin-2) insufficiency is associated with combined allergic and infectious respiratory disease in children. Mol. Immunol. 2009, 47:415-419.
143. Chapman S.J., Vannberg F.O., Khor C.C., et al. Functional polymorphisms in the FCN2 gene are not associated with invasive pneumococcal disease. Mol. Immunol. 2007, 44:3267-3270.
144. Swierzko A.S., Atkinson A.P., Cedzynski M., et al. Two factors of the lectin pathway of complement, l-ficolin and mannan-binding lectin, and their associations with prematurity, low birthweight and infections in a large cohort of Polish neonates. Mol. Immunol. 2009, 46:551-558.
145. de Messias-Reason I., Kremsner P.G., Kun J.F. Functional haplotypes that produce normal ficolin-2 levels protect against clinical leprosy. J. Infect. Dis. 2009, 199:801-804.
146. Faik I., Oyedeji S.I., Idris Z., et al. Ficolin-2 levels and genetic polymorphisms of FCN2 in malaria. Hum. Immunol. 2010, 72:74-79.
147. Inaba S., Okochi K., Yae Y., Niklasson F., de Verder C.H. Serological studies of an SLE-associated antigen-antibody system discovered as a precipitation reaction in agarose gel: the HAKATA antigen-antibody system. Fukuoka Igaku Zasshi 1990, 81:284-291.
148. Garred P., Borregaard N. The ficolins. J. Innate Immun. 2009, 2:1-2.
149. Garred P., Honore C., Ma Y.J., et al. The genetics of ficolins. J. Innate Immun. 2009, 2:3-16.
150. Endo Y., Liu Y., Kanno K., Takahashi M., Matsushita M., Fujita T. Identification of the mouse H-ficolin gene as a pseudogene and orthology between mouse ficolins A/B and human L-/M-ficolins. Genomics 2004, 84:737-744.
151. Akaiwa M., Yae Y., Sugimoto R., et al. Hakata antigen, a new member of the ficolin/opsonin p35 family, is a novel human lectin secreted into bronchus/alveolus and bile. J. Histochem. Cytochem. 1999, 47:777-786.
152. Luo J.H., Ren B., Keryanov S., et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 2006, 44:1012-1024.
153. Imai N., Nishi S., Alchi B., et al. Immunohistochemical evidence of activated lectin pathway in kidney allografts with peritubular capillary C4d deposition. Nephrol. Dial. Transplant. 2006, 21:2589-2595.
154. Lacroix M., Dumestre-Perard C., Schoehn G., et al. Residue Lys57 in the collagen-like region of human L-ficolin and its counterpart Lys47 in H-ficolin play a key role in the interaction with the mannan-binding lectin-associated serine proteases and the collectin receptor calreticulin. J. Immunol. 2009, 182:456-465.
155. Tsujimura M., Miyazaki T., Kojima E., et al. Serum concentration of Hakata antigen, a member of the ficolins, is linked with inhibition of Aerococcus viridans growth. Clin. Chim. Acta 2002, 325:139-146.
156. Honore C., Hummelshoj T., Hansen B.E., Madsen H.O., Eggleton P., Garred P. The innate immune component ficolin 3 (Hakata antigen) mediates the clearance of late apoptotic cells. Arthritis Rheum. 2007, 56:1598-1607.
157. Kilpatrick D.C., Fujita T., Matsushita M. P35, an opsonic lectin of the ficolin family, in human blood from neonates, normal adults, and recurrent miscarriage patients. Immunol. Lett. 1999, 67:109-112.
158. Munthe-Fog L., Hummelshoj T., Ma Y.J., et al. Characterization of a polymorphism in the coding sequence of FCN3 resulting in a Ficolin-3 (Hakata antigen) deficiency state. Mol. Immunol. 2008, 45:2660-2666.
159. Munthe-Fog L., Hummelshoj T., Honore C., Madsen H.O., Permin H., Garred P. Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency. N. Engl. J. Med. 2009, 360:2637-2644.
160. Schlapbach L.J., Thiel S., Kessler U., Ammann R.A., Aebi C., Jensenius J.C. Congenital H-ficolin deficiency in premature infants with severe necrotising enterocolitis. Gut 2011, 60(10):1438-1439. letter online first.
161. Hein E., Honore C., Skjoedt M.O., Munthe-Fog L., Hummelshoj T., Garred P. Functional analysis of Ficolin-3 mediated complement activation. PLoS One 2010, 5:e15443.
162. Endo Y., Takahashi M., Nakao M., et al. Two lineages of mannose-binding lectin-associated serine protease (MASP) in vertebrates. J. Immunol. 1998, 161:4924-4930.
163. Matsushita M., Fujita T. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. J. Exp. Med. 1992, 176:1497-1502.
164. Thiel S., Vorup-Jensen T., Stover C.M., et al. A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997, 386:506-510.
165. Dahl M.R., Thiel S., Matsushita M., et al. MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity 2001, 15:127-135.
166. Matsushita M., Endo Y., Hamasaki N., Fujita T. Activation of the lectin complement pathway by ficolins. Int. Immunopharmacol. 2001, 1:359-363.
167. Matsushita M., Kuraya M., Hamasaki N., Tsujimura M., Shiraki H., Fujita T. Activation of the lectin complement pathway by H-ficolin (Hakata antigen). J. Immunol. 2002, 168:3502-3506.
168. Skjoedt M.O., Hummelshoj T., Palarasah Y., et al. A novel mannose-binding lectin/ficolin-associated protein is highly expressed in heart and skeletal muscle tissues and inhibits complement activation. J. Biol. Chem. 2010, 285:8234-8243.
169. Chen C.B., Wallis R. Stoichiometry of complexes between mannose-binding protein and its associated serine proteases. Defining functional units for complement activation. J. Biol. Chem. 2001, 276:25894-25902.
170. Rossi V., Cseh S., Bally I., Thielens N.M., Jensenius J.C., Arlaud G.J. Substrate specificities of recombinant mannan-binding lectin-associated serine proteases-1 and-2. J. Biol. Chem. 2001, 276:40880-40887.
171. Mayilyan K.R., Presanis J.S., Arnold J.N., Hajela K., Sim R.B. Heterogeneity of MBL-MASP complexes. Mol. Immunol. 2006, 43:1286-1292.
172. Takada F., Seki N., Matsuda Y., Takayama Y., Kawakami M. Localization of the genes for the 100-kDa complement-activating components of Ra-reactive factor (CRARF and Crarf) to human 3q27-q28 and mouse 16B2-B3. Genomics 1995, 25:757-759.
173. Terai I., Kobayashi K., Matsushita M., Fujita T. Human serum mannose-binding lectin (MBL)-associated serine protease-1 (MASP-1): determination of levels in body fluids and identification of two forms in serum. Clin. Exp. Immunol. 1997, 110:317-323.
174. Dobo J., Harmat V., Beinrohr L., Sebestyen E., Zavodszky P., Gal P. MASP-1, a promiscuous complement protease: structure of its catalytic region reveals the basis of its broad specificity. J. Immunol. 2009, 183:1207-1214.
175. Moller-Kristensen M., Thiel S., Sjoholm A., Matsushita M., Jensenius J.C. Cooperation between MASP-1 and MASP-2 in the generation of C3 convertase through the MBL pathway. Int. Immunol. 2007, 19:141-149.
176. Petersen S.V., Thiel S., Jensenius J.C. The mannan-binding lectin pathway of complement activation: biology and disease association. Mol. Immunol. 2001, 38:133-149.
177. Takahashi M., Iwaki D., Kanno K., et al. Mannose-binding lectin (MBL)-associated serine protease (MASP)-1 contributes to activation of the lectin complement pathway. J. Immunol. 2008, 180:6132-6138.
178. Takahashi M., Ishida Y., Iwaki D., et al. Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D. J. Exp. Med. 2010, 207:29-37.
179. Hajela K., Kojima M., Ambrus G., et al. The biological functions of MBL-associated serine proteases (MASPs). Immunobiology 2002, 205:467-475.
180. Takahashi K., Chang W.C., Takahashi M., et al. Mannose-binding lectin and its associated proteases (MASPs) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation. Immunobiology 2011, 216:96-102.
181. Presanis J.S., Hajela K., Ambrus G., Gal P., Sim R.B. Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Mol. Immunol. 2004, 40:921-929.
182. Megyeri M., Mako V., Beinrohr L., et al. Complement protease MASP-1 activates human endothelial cells: PAR4 activation is a link between complement and endothelial function. J. Immunol. 2009, 183:3409-3416.
183. Stover C.M., Lynch N.J., Dahl M.R., et al. Murine serine proteases MASP-1 and MASP-3, components of the lectin pathway activation complex of complement, are encoded by a single structural gene. Genes Immun. 2003, 4:374-384.
184. Cortesio C.L., Jiang W. Mannan-binding lectin-associated serine protease 3 cleaves synthetic peptides and insulin-like growth factor-binding protein 5. Arch. Biochem. Biophys. 2006, 449:164-170.
185. Brown K.S., Keogh M.J., Tagiuri N., et al. Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex. Clin. Exp. Immunol. 2007, 147:90-98.
186. Hisano S., Matsushita M., Fujita T., Takeshita M., Iwasaki H. Activation of the lectin complement pathway in post-streptococcal acute glomerulonephritis. Pathol. Int. 2007, 57:351-357.
187. Stover C.M., Schwaeble W.J., Lynch N.J., Thiel S., Speicher M.R. Assignment of the gene encoding mannan-binding lectin-associated serine protease 2 (MASP2) to human chromosome 1p36.3->p36.2 by in situ hybridization and somatic cell hybrid analysis. Cytogenet. Cell Genet. 1999, 84:148-149.
188. Unterberger C., Hanson S., Klingenhoff A., et al. Stat3 is involved in control of MASP2 gene expression. Biochem. Biophys. Res. Commun. 2007, 364:1022-1025.
189. Stover C., Endo Y., Takahashi M., et al. The human gene for mannan-binding lectin-associated serine protease-2 (MASP-2), the effector component of the lectin route of complement activation, is part of a tightly linked gene cluster on chromosome 1p36.2-3. Genes Immun. 2001, 2:119-127.
190. Feinberg H., Uitdehaag J.C., Davies J.M., Wallis R., Drickamer K., Weis W.I. Crystal structure of the CUB1-EGF-CUB2 region of mannose-binding protein associated serine protease-2. EMBO J. 2003, 22:2348-2359.
191. Thiel S., Kolev M., Degn S., et al. Polymorphisms in mannan-binding lectin (MBL)-associated serine protease 2 affect stability, binding to MBL, and enzymatic activity. J. Immunol. 2009, 182:2939-2947.
192. Gal P., Harmat V., Kocsis A., et al. A true autoactivating enzyme. Structural insight into mannose-binding lectin-associated serine protease-2 activations. J. Biol. Chem. 2005, 280:33435-33444.
193. Kerr F.K., Thomas A.R., Wijeyewickrema L.C., et al. Elucidation of the substrate specificity of the MASP-2 protease of the lectin complement pathway and identification of the enzyme as a major physiological target of the serpin, C1-inhibitor. Mol. Immunol. 2008, 45:670-677.
194. Gulla K.C., Gupta K., Krarup A., et al. Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology 2010, 129:482-495.
195. Stover C.M., Thiel S., Thelen M., et al. Two constituents of the initiation complex of the mannan-binding lectin activation pathway of complement are encoded by a single structural gene. J. Immunol. 1999, 162:3481-3490.
196. Takahashi M., Endo Y., Fujita T., Matsushita M. A truncated form of mannose-binding lectin-associated serine protease (MASP)-2 expressed by alternative polyadenylation is a component of the lectin complement pathway. Int. Immunol. 1999, 11:859-863.
197. Stengaard-Pedersen K., Thiel S., Gadjeva M., et al. Inherited deficiency of mannan-binding lectin-associated serine protease 2. N. Engl. J. Med. 2003, 349:554-560.
198. Thiel S., Steffensen R., Christensen I.J., et al. Deficiency of mannan-binding lectin associated serine protease-2 due to missense polymorphisms. Genes Immun. 2007, 8:154-163.
199. Valles X., Sarrias M.R., Casals F., et al. Genetic and structural analysis of MBL2 and MASP2 polymorphisms in south-eastern African children. Tissue Antigens 2009, 74:298-307.
200. Ytting H., Christensen I.J., Thiel S., et al. Biological variation in circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease-2 and the influence of age, gender and physical exercise. Scand. J. Immunol. 2007, 66:458-464.
201. Moller-Kristensen M., Jensenius J.C., Jensen L., et al. Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals. J. Immunol. Methods 2003, 282:159-167.
202. Garcia-Laorden M.I., Sole-Violan J., Rodriguez de C.F., et al. Mannose-binding lectin and mannose-binding lectin-associated serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults. J. Allergy Clin. Immunol. 2008, 122:368-374.
203. Garcia-Laorden M.I., Garcia-Saavedra A., de Castro F.R., et al. Low clinical penetrance of mannose-binding lectin-associated serine protease 2 deficiency. J. Allergy Clin. Immunol. 2006, 118:1383-1386.
204. Ramasawmy R., Spina G.S., Fae K.C., et al. Association of mannose-binding lectin gene polymorphism but not of mannose-binding serine protease 2 with chronic severe aortic regurgitation of rheumatic etiology. Clin. Vaccine Immunol. 2008, 15:932-936.
205. Schafranski M.D., Pereira F.L., Scherner D., Torres R., de Messias-Reason I.J. Functional MASP2 gene polymorphism in patients with history of rheumatic fever. Hum. Immunol. 2008, 69:41-44.
206. Olesen H.V., Jensenius J.C., Steffensen R., Thiel S., Schiotz P.O. The mannan-binding lectin pathway and lung disease in cystic fibrosis-disfunction of mannan-binding lectin-associated serine protease 2 (MASP-2) may be a major modifier. Clin. Immunol. 2006, 121:324-331.
207. Miller C., Wilgenbusch S., Michaels M., Chi D.S., Youngberg G., Krishnaswamy G. Molecular defects in the mannose binding lectin pathway in dermatological disease: case report and literature review. Clin. Mol. Allergy 2010, 8:6.
208. Bouwman L.H., Roep B.O., Roos A. Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity. Hum. Immunol. 2006, 67:247-256.
209. Lee D.M., Weinblatt M.E. Rheumatoid arthritis. Lancet 2001, 358:903-911.
210. Ozbalkan Z., Efe C., Cesur M., et al. An update on the relationships between rheumatoid arthritis and atherosclerosis. Atherosclerosis 2010, 212:377-382.
211. Turesson C., O'Fallon W.M., Crowson C.S., Gabriel S.E., Matteson E.L. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J. Rheumatol. 2002, 29:62-67.
212. Carmona L., Gonzalez-Alvaro I., Balsa A., Angel B.M., Tena X., Sanmarti R. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann. Rheum. Dis. 2003, 62:897-900.
213. Brooks P.M. The burden of musculoskeletal disease-a global perspective. Clin. Rheumatol. 2006, 25:778-781.
214. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361.
215. Shahrara S., Huang Q., Mandelin A.M., Pope R.M. TH-17 cells in rheumatoid arthritis. Arthritis Res. Ther. 2008, 10:R93.
216. Ospelt C., Brentano F., Rengel Y., et al. Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum. 2008, 58:3684-3692.
217. Goeldner I., Skare T.L., de Messias Reason I.T., Nisihara R.M., Silva M.B., Utiyama S.R. Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in rheumatoid arthritis patients and relatives from Brazil. Rheumatology (Oxford) 2010, 49:1590-1593.
218. Isaacs J.D., Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann. Rheum. Dis. 2010, 70(1):4-7.
219. Prokopec K.E., Rhodiner M., Matt P., Lindqvist U., Kleinau S. Down regulation of Fc and complement receptors on B cells in rheumatoid arthritis. Clin. Immunol. 2010, 137:322-329.
220. Sato R., Matsushita M., Miyata M., Sato Y., Kasukawa R., Fujita T. Substances reactive with mannose-binding protein (MBP) in sera of patients with rheumatoid arthritis. Fukushima J. Med. Sci. 1997, 43:99-111.
221. Graudal N.A., Madsen H.O., Tarp U., et al. The association of variant mannose-binding lectin genotypes with radiographic outcome in rheumatoid arthritis. Arthritis Rheum. 2000, 43:515-521.
222. Ip W.K., Lau Y.L., Chan S.Y., et al. Mannose-binding lectin and rheumatoid arthritis in southern Chinese. Arthritis Rheum. 2000, 43:1679-1687.
223. Saevarsdottir S., Vikingsdottir T., Vikingsson A., Manfredsdottir V., Geirsson A.J., Valdimarsson H. Low mannose binding lectin predicts poor prognosis in patients with early rheumatoid arthritis. A prospective study. J. Rheumatol. 2001, 28:728-734.
224. Graudal N. The natural history and prognosis of rheumatoid arthritis: association of radiographic outcome with process variables, joint motion and immune proteins. Scand. J. Rheumatol. 2004, 118:1-38.
225. Jacobsen S., Madsen H.O., Klarlund M., et al. The influence of mannose binding lectin polymorphisms on disease outcome in early polyarthritis. TIRA Group. J. Rheumatol. 2001, 28:935-942.
226. Graudal N.A., Homann C., Madsen H.O., et al. Mannan binding lectin in rheumatoid arthritis. A longitudinal study. J. Rheumatol. 1998, 25:629-635.
227. Garred P., Madsen H.O., Marquart H., et al. Two edged role of mannose binding lectin in rheumatoid arthritis: a cross sectional study. J. Rheumatol. 2000, 27:26-34.
228. Maury C.P., Aittoniemi J., Tiitinen S., Laiho K., Kaarela K., Hurme M. Variant mannose-binding lectin 2 genotype is a risk factor for reactive systemic amyloidosis in rheumatoid arthritis. J. Intern. Med. 2007, 262:466-469.
229. Barton A., Platt H., Salway F., et al. Polymorphisms in the mannose binding lectin (MBL) gene are not associated with radiographic erosions in rheumatoid or inflammatory polyarthritis. J. Rheumatol. 2004, 31:442-447.
230. Soell M., Lett E., Holveck F., Scholler M., Wachsmann D., Klein J.P. Activation of human monocytes by streptococcal rhamnose glucose polymers is mediated by CD14 antigen, and mannan binding protein inhibits TNF-alpha release. J. Immunol. 1995, 154:851-860.
231. Chaka W., Verheul A.F., Vaishnav V.V., et al. Induction of TNF-alpha in human peripheral blood mononuclear cells by the mannoprotein of Cryptococcus neoformans involves human mannose binding protein. J. Immunol. 1997, 159:2979-2985.
232. Summerfield J.A. Clinical potential of mannose-binding lectin-replacement therapy. Biochem. Soc. Trans. 2003, 31:770-773.
233. Gupta K., Gupta R.K., Hajela K. Disease associations of mannose-binding lectin & potential of replacement therapy. Indian J. Med. Res. 2008, 127:431-440.
234. Troelsen L.N., Garred P., Madsen H.O., Jacobsen S. Genetically determined high serum levels of mannose-binding lectin and agalactosyl IgG are associated with ischemic heart disease in rheumatoid arthritis. Arthritis Rheum. 2007, 56:21-29.
235. Troelsen L.N., Garred P., Jacobsen S. Mortality and predictors of mortality in rheumatoid arthritis-a role for mannose-binding lectin?. J. Rheumatol. 2010, 37:536-543.
236. Young A., Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 2007, 21:907-927.
237. Dhawan S.S., Quyyumi A.A. Rheumatoid arthritis and cardiovascular disease. Curr. Atheroscler. Rep. 2008, 10:128-133.
238. Jacobsen S., Garred P., Madsen H.O., et al. Mannose-binding lectin gene polymorphisms are associated with disease activity and physical disability in untreated, anti-cyclic citrullinated peptide-positive patients with early rheumatoid arthritis. J. Rheumatol. 2009, 36:731-735.
239. Gupta B., Agrawal C., Raghav S.K., et al. Association of mannose-binding lectin gene (MBL2) polymorphisms with rheumatoid arthritis in an Indian cohort of case-control samples. J. Hum. Genet. 2005, 50:583-591.
240. Saevarsdottir S., Steinsson K., Grondal G., Valdimarsson H. Patients with rheumatoid arthritis have higher levels of mannan-binding lectin than their first-degree relatives and unrelated controls. J. Rheumatol. 2007, 34:1692-1695.
241. Gupta B., Raghav S.K., Agrawal C., Chaturvedi V.P., Das R.H., Das H.R. Anti-MBL autoantibodies in patients with rheumatoid arthritis: prevalence and clinical significance. J. Autoimmun. 2006, 27:125-133.
242. Vander C.B., Nuytinck L., Boullart L., et al. Polymorphisms in the ficolin 1 gene (FCN1) are associated with susceptibility to the development of rheumatoid arthritis. Rheumatology (Oxford) 2007, 46:1792-1795.
243. Bovin L.F., Brynskov J., Hegedus L., Jess T., Nielsen C.H., Bendtzen K. Gene expression profiling in autoimmune diseases: chronic inflammation or disease specific patterns?. Autoimmunity 2007, 40:191-201.
244. Banda N.K., Takahashi M., Levitt B., et al. Essential role of complement mannose-binding lectin-associated serine proteases-1/3 in the murine collagen antibody-induced model of inflammatory arthritis. J. Immunol. 2010, 185:5598-5606.
245. Orozco G., Eyre S., Hinks A., et al. Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. Ann. Rheum. Dis. 2010, 70:463-468.
246. Dooley M.A., Hogan S., Jennette C., Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int. 1997, 51:1188-1195.
247. Espeli M., Bokers S., Giannico G., et al. Local renal autoantibody production in lupus nephritis. J. Am. Soc. Nephrol. 2010, 22:296-305.
248. Lee H.M., Sugino H., Nishimoto N. Cytokine networks in systemic lupus erythematosus. J. Biomed. Biotechnol. 2010, 2010:676284.
249. Chen M., Daha M.R., Kallenberg C.G. The complement system in systemic autoimmune disease. J. Autoimmun. 2010, 34:J276-J286.
250. Lee Y.H., Witte T., Momot T., et al. The mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: two case-control studies and a meta-analysis. Arthritis Rheum. 2005, 52:3966-3974.
251. Tsutsumi A., Sasaki K., Wakamiya N., et al. Mannose-binding lectin gene: polymorphisms in Japanese patients with systemic lupus erythematosus, rheumatoid arthritis and Sjogren's syndrome. Genes Immun. 2001, 2:99-104.
252. Piao W., Liu C.C., Kao A.H., et al. Mannose-binding lectin is a disease-modifying factor in North American patients with systemic lupus erythematosus. J. Rheumatol. 2007, 34:1506-1513.
253. Seelen M.A., van der Bijl E.A., Trouw L.A., et al. A role for mannose-binding lectin dysfunction in generation of autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2005, 44:111-119.
254. Saevarsdottir S., Steinsson K., Ludviksson B.R., Grondal G., Valdimarsson H. Mannan-binding lectin may facilitate the clearance of circulating immune complexes-implications from a study on C2-deficient individuals. Clin. Exp. Immunol. 2007, 148:248-253.
255. Bultink I.E., Hamann D., Seelen M.A., et al. Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus. Arthritis Res. Ther. 2006, 8:R183.
256. Ip W.K., Chan S.Y., Lau C.S., Lau Y.L. Association of systemic lupus erythematosus with promoter polymorphisms of the mannose-binding lectin gene. Arthritis Rheum. 1998, 41:1663-1668.
257. Huang Y.F., Wang W., Han J.Y., et al. Increased frequency of the mannose-binding lectin LX haplotype in Chinese systemic lupus erythematosus patients. Eur. J. Immunogenet. 2003, 30:121-124.
258. Jakab L., Laki J., Sallai K., et al. Association between early onset and organ manifestations of systemic lupus erythematosus (SLE) and a down-regulating promoter polymorphism in the MBL2 gene. Clin. Immunol. 2007, 125:230-236.
259. Font J., Ramos-Casals M., Brito-Zeron P., et al. Association of mannose-binding lectin gene polymorphisms with antiphospholipid syndrome, cardiovascular disease and chronic damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2007, 46:76-80.
260. Ohlenschlaeger T., Garred P., Madsen H.O., Jacobsen S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N. Engl. J. Med. 2004, 351:260-267.
261. Calvo-Alen J., Alarcon G.S., Tew M.B., et al. Systemic lupus erythematosus in a multiethnic US cohort: XXXIV. Deficient mannose-binding lectin exon 1 polymorphisms are associated with cerebrovascular but not with other arterial thrombotic events. Arthritis Rheum. 2006, 54:1940-1945.
262. Garred P., Madsen H.O., Halberg P., et al. Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum. 1999, 42:2145-2152.
263. Garred P., Voss A., Madsen H.O., Junker P. Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients. Genes Immun. 2001, 2:442-450.
264. Takahashi R., Tsutsumi A., Ohtani K., et al. Association of mannose binding lectin (MBL) gene polymorphism and serum MBL concentration with characteristics and progression of systemic lupus erythematosus. Ann. Rheum. Dis. 2005, 64:311-314.
265. Mok M.Y., Ip W.K., Lau C.S., Lo Y., Wong W.H., Lau Y.L. Mannose-binding lectin and susceptibility to infection in Chinese patients with systemic lupus erythematosus. J. Rheumatol. 2007, 34:1270-1276.
266. Davies E.J., Teh L.S., Ordi-Ros J., et al. A dysfunctional allele of the mannose binding protein gene associates with systemic lupus erythematosus in a Spanish population. J. Rheumatol. 1997, 24:485-488.
267. Saevarsdottir S., Kristjansdottir H., Grondal G., Vikingsdottir T., Steinsson K., Valdimarsson H. Mannan-binding lectin and complement C4A in Icelandic multicase families with systemic lupus erythematosus. Ann. Rheum. Dis. 2006, 65:1462-1467.
268. Villarreal J., Crosdale D., Ollier W., et al. Mannose binding lectin and FcgammaRIIa (CD32) polymorphism in Spanish systemic lupus erythematosus patients. Rheumatology (Oxford) 2001, 40:1009-1012.
269. Seelen M.A., Trouw L.A., van der Hoorn J.W., et al. Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. Clin. Exp. Immunol. 2003, 134:335-343.
270. Shoenfeld Y., Szyper-Kravitz M., Witte T., et al. Autoantibodies against protective molecules-C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 2007, 1108:227-239.
271. Andersen T., Munthe-Fog L., Garred P., Jacobsen S. Serum levels of ficolin-3 (Hakata antigen) in patients with systemic lupus erythematosus. J. Rheumatol. 2009, 36:757-759.
272. Weiss G., Madsen H.O., Garred P. A novel mannose-binding lectin-associated serine protease 1/3 gene variant. Scand. J. Immunol. 2007, 65:430-434.
273. Carapetis J.R., McDonald M., Wilson N.J. Acute rheumatic fever. Lancet 2005, 366:155-168.
274. Homer C., Shulman S.T. Clinical aspects of acute rheumatic fever. J. Rheumatol. Suppl. 1991, 29:2-13.
275. Steer A.C., Carapetis J.R., Nolan T.M., Shann F. Systematic review of rheumatic heart disease prevalence in children in developing countries: the role of environmental factors. J. Paediatr. Child Health 2002, 38:229-234.
276. Neth O., Jack D.L., Dodds A.W., Holzel H., Klein N.J., Turner M.W. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect. Immun. 2000, 68:688-693.
277. Nayar S., Nayar P.G., Cherian K.M. Heart valve structure: a predisposing factor for rheumatic heart disease. Heart 2006, 92:1151-1152.
278. de Messias I.J., Cavalcanti E., Radominski S.C. Increased frequency of the C4A*6 rare allele in rheumatic heart disease. Scand. J. Rheumatol. 1995, 24:164-168.
279. Messias-Reason I.J., Schafranski M.D., Kremsner P.G., Kun J.F. Ficolin 2 (FCN2) functional polymorphisms and the risk of rheumatic fever and rheumatic heart disease. Clin. Exp. Immunol. 2009, 157:395-399.
280. Moutsopoulos H.M. Sjogren's syndrome: autoimmune epithelitis. Clin. Immunol. Immunopathol. 1994, 72:162-165.
281. Karaiskos D., Mavragani C.P., Sinno M.H., et al. Psychopathological and personality features in primary Sjogren's syndrome-associations with autoantibodies to neuropeptides. Rheumatology (Oxford) 2010, 49:1762-1769.
282. Theander E., Manthorpe R., Jacobsson L.T. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum. 2004, 50:1262-1269.
283. Steinfeld S., Penaloza A., Ribai P., et al. D-mannose and N-acetylglucosamine moieties and their respective binding sites in salivary glands of Sjogren's syndrome. J. Rheumatol. 1999, 26:833-841.
284. Ramos-Casals M., Brito-Zeron P., Soria N., et al. Mannose-binding lectin-low genotypes are associated with milder systemic and immunological disease expression in primary Sjogren's syndrome. Rheumatology (Oxford) 2009, 48:65-69.
285. Aittoniemi J., Pertovaara M., Hulkkonen J., et al. The significance of mannan-binding lectin gene alleles in patients with primary Sjogren's syndrome. Scand. J. Rheumatol. 2002, 31:362-365.
286. Wang Z.Y., Morinobu A., Kanagawa S., Kumagai S. Polymorphisms of the mannose binding lectin gene in patients with Sjogren's syndrome. Ann. Rheum. Dis. 2001, 60:483-486.
287. Na S.J., Kim S.M., Sunwoo I.N., Choi Y.C. Clinical characteristics and outcomes of juvenile and adult dermatomyositis. J. Korean Med. Sci. 2009, 24:715-721.
288. Callen J.P., Wortmann R.L. Dermatomyositis. Clin. Dermatol. 2006, 24:363-373.
289. Dalakas M.C., Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003, 362:971-982.
290. Werth V.P., Berlin J.A., Callen J.P., Mick R., Sullivan K.E. Mannose binding lectin (MBL) polymorphisms associated with low MBL production in patients with dermatomyositis. J. Invest. Dermatol. 2002, 119:1394-1399.
291. Salvarani C., Cantini F., Boiardi L., Hunder G.G. Polymyalgia rheumatica and giant-cell arteritis. N. Engl. J. Med. 2002, 347:261-271.
292. Weyand C.M., Ma-Krupa W., Goronzy J.J. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun. Rev. 2004, 3:46-53.
293. Jacobsen S., Baslund B., Madsen H.O., Tvede N., Svejgaard A., Garred P. Mannose-binding lectin variant alleles and HLA-DR4 alleles are associated with giant cell arteritis. J. Rheumatol. 2002, 29:2148-2153.
294. Tam L.S., Gu J., Yu D. Pathogenesis of ankylosing spondylitis. Nat. Rev. Rheumatol. 2010, 6:399-405.
295. Ebringer A., Rashid T. B27 disease is a new autoimmune disease that affects millions of people. Ann. N. Y. Acad. Sci. 2007, 1110:112-120.
296. Aydin S.Z., Atagunduz P., Erer B., Bahadir C., Inanc N., Direskeneli H. Mannose binding lectin levels are not related to radiographic damage in ankylosing spondylitis. Rheumatol. Int. 2010, 30:415-417.
297. Locht H., Christiansen M., Laursen I. Reactive arthritis and serum levels of mannose binding lectin-lack of association. Clin. Exp. Immunol. 2003, 131:169-173.